@article{e7356e5554e0417890959a280b98bdb7,
title = "Anaplastic Thyroid Cancer: New Horizons and Challenges",
keywords = "Anaplastic thyroid cancer, BRAF/MEK inhibitor, Clinical trial, Immunotherapy, Multidisciplinary, Surgery, Targeted therapy",
author = "Anastasios Maniakas and Mark Zafereo and Cabanillas, {Maria E.}",
note = "Funding Information: A. Maniakas declares no competing interests. M. Zafereo: principal investigator for clinical trials funded by Merck and Eli Lilly . M.E. Cabanillas: research funding from Eisai , Exelixis , Kura Oncology , and Genentech ; participated in advisory boards for LOXO, Bayer, and Ignyta.",
year = "2022",
month = jun,
doi = "10.1016/j.ecl.2021.11.020",
language = "English (US)",
volume = "51",
pages = "391--401",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "2",
}